Skip to content

Geriatric Lateral Compression 1 Pelvic Fractures

Percutaneous Screw Fixation for Operative Treatment Versus Non-Operative Treatment of Geriatric Lateral Compression 1 Pelvic Fractures - A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05765669
Enrollment
50
Registered
2023-03-13
Start date
2023-05-05
Completion date
2025-11-18
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Compression 1 Pelvic Fracture

Keywords

Lateral compression, Operative, Non-operative, Fragility fracture, Pelvic fracture, Percutaneous pelvis screw, Osteoporosis

Brief summary

Lateral compression-1 (LC1) pelvic ring fragility fractures cause significant pain and morbidity. These fragility injuries are associated with prolonged immobility and long hospital stays. Currently there is no consensus on operative stabilization of LC1 pelvic fractures, nor are there evidence-based guidelines to aid in management of these injury types. Furthermore, there is variability in operative indications, improvement in pain and mobilization. The purpose of this study is to compare percutaneous screw fixation to non-operative management in symptomatic LC1 fragility fractures in elderly patients.

Detailed description

This study is a prospective, randomized control trial (RCT) of 100 patients with fragility pelvic ring fractures. All patients presenting with pelvic ring fractures classified as LC1 confirmed with plain radiographs, CT and/or MRI, resulting from a low energy mechanism or an insufficiency fracture without a precipitating event will undergo a trial of physical therapy with mobilization and multimodal pain management. If the subject has substantial posterior pelvic pain (score ≥ 7 with the Visual Analogue Scale (VAS)) or inability to ambulate after the physical therapy trial for 48 hours, the subject is eligible for enrollment in the RCT. Patients will either be grouped into an operative group, defined as percutaneous screw fixation, or a nonoperative group, defined as treatment with physical therapy and pain management only. 1. Group 1-Operative treatment: Percutaneous screw fixation will be performed for stabilization of the pelvic fracture 2. Group 2-Conservative (non-operative) treatment: Pain management and physical therapy advanced with weight bearing as tolerated.

Interventions

PROCEDUREPercutaneous screw fixation

Surgical intervention in the form of percutaneous screw fixation

OTHERPain management

Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated

OTHERPhysical therapy

Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated

Sponsors

HealthPartners Institute
Lead SponsorOTHER
Orthopaedic Trauma Association
CollaboratorOTHER
Allina Health System
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients \>/= 60 years of age * Lateral compression 1 pelvic ring fractures confirmed with plain radiographs, CT and/or MRI * Low energy mechanism of injury or an insufficiency fracture without a precipitating event * Acute injury within four weeks of presentation * Inability or significant pain to mobilize with physical therapy assistance for 48 hours: Significant pain as determined by a pain score ≥ 7 with the Visual Analogue Scale (VAS) after a Timed "Up \& Go" (TUG) assessment, or inability to complete the TUG assessment.

Exclusion criteria

* Dementia * Vertically or rotationally unstable pelvic ring injuries * Pathologic fracture secondary to tumor * Non-ambulatory prior to injury * Acute neurologic deficit * High-energy mechanism of injury * Concomitant injuries affecting ambulation * Presence of another injury or medical condition that prevents ambulation * Presence of implant or sacral morphology that prevents percutaneous sacral fixation * Enrollment in another research study the precludes co-enrollment * Likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, etc.) * Incarcerated or pending incarceration

Design outcomes

Primary

MeasureTime frameDescription
Timed Up and Go (TUG) assessmentDay 2 after treatmentValid outcome that measures mobility for elderly patients. The TUG assessment measures the time it takes for a patient, with assistance of physical therapy to get up from a chair, walk 3 meters turn around walk 3 meters back to the chair and sit down.

Secondary

MeasureTime frameDescription
Sacral Region Pain by Visual Analog ScaleDay 2, 2 weeks, 6 weeks, and 3 months after treatmentPatient reported pain on a scale of 0-10. Minimum score 0 (no pain) to maximum score 10 (worst possible pain)
Timed Up and Go (TUG) assessment2 weeks, 6 weeks, and 3 months after treatmentValid outcome that measures mobility for elderly patients. The TUG assessment measures the time it takes for a patient, with assistance of physical therapy to get up from a chair, walk 3 meters turn around walk 3 meters back to the chair and sit down.
Discharge Disposition LocationPost discharge from treatment, an average of 5 days from being admitted to the hospitalWhere a patient went after being discharged from the hospital (home, rehabilitation center, skilled nursing facility)
Longest Distance of AmbulationDay 2 after treatmentHow far a patient was able to walk
Use of Narcotic Pain MedicationDay 2 after treatmentUse of narcotic pain medication, total in milligram equivalents (MME)
Hospital Length of StayPost discharge from treatment, an average of 5 days from being admitted to the hospitalNumber of days admitted to hospital during treatment
Rate of Complications2 weeks, 6 weeks, and 3 months after treatmentUnplanned surgery, new neurological deficit after treatment, surgical site infection, re-admission, decubitus ulcer, pneumonia, deep vein thrombosis, pulmonary embolism, delirium, myocardial infarction, 90 days mortality

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMai P. Nguyen, MD

University of Minnesota and HealthPartners

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026